NOT KNOWN DETAILS ABOUT TRASTUZUMAB PACKAGE INSERT

The most beneath-investigated “driving forces” associated with trastuzumab resistance is PTEN. Nagata et al. (2004) claimed that the lack of PTEN was noticed in 36% of HER2-beneficial Principal breast tumor specimens from people with stage IV disease. In addition, they also showed that individuals with PTEN-deficient tumors experienced remarkab